Cluster Headache Market
- The Cluster Headache Market is expected to experience steady growth during the forecast period (2023–2032). This growth can be attributed to the increasing prevalence of Cluster Headaches in all populations, including the pediatric pool, and increasing research and development efforts for new therapies targeting curative paradigms.
- DelveInsight’s analysts estimated that there has been an increase in Cluster Headache occurrences in recent years, which may be attributed to factors such as improved awareness of diagnosis advancements and a lifestyle change which includes diet overall, there is an increase in stress levels of the population, which is further increasing the cases of cluster headaches.
- To drive the Cluster Headache Market in future years, companies like Lundbeck, Clexio Biosciences, and others are developing their assets. With the expected approval of all these therapies currently under development, the overall therapeutic market of Cluster Headaches is likely to rise at a significant CAGR during the forecast period (2023–2032).
DelveInsight’s “Cluster Headache Market Insights, Epidemiology, and Market Forecast – 2032” comprehensively analyzes Cluster Headache. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Cluster Headaches segmented by gender-specific, age-specific, and type-specific cases. The Cluster Headache market report offers an in-depth understanding of the various aspects related to the patient population, including diagnosis, prescription patterns, physician perspectives, market access, treatment, and future market developments for the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2019 to 2032.
The report discusses current Cluster Headache treatment practices, algorithms, and unmet medical needs to gauge the market’s overall potential and identify business opportunities.
Cluster Headache Treatment Market
Diagnosing Cluster Headache requires a thorough assessment of autonomic symptoms, a thorough history, diagnostic tests, and imaging tests like CT scans or MRI. However, the diagnosis of Cluster Headache poses challenges due to the overlap of symptoms with other conditions, such as migraine, so it is often misdiagnosed. There is no single definitive test for confirming cluster headaches, and due to the rare nature of the disease, the physicians also do not have much experience in recognizing it.
Cluster Headache currently lacks a cure; treatment aims for symptomatic relief, shortening the periods of headaches, and reducing their frequency. The approach to treatment is tailored to the individual’s symptoms. Medications and treatments for cluster headaches aim to prevent them or act quickly. Over-the-counter (OTC) pain medication such as aspirin or ibuprofen can be too slow to reduce pain before the headache is over effectively.
Cluster headache often occurs in the pediatric population, although they are typically not diagnosed until adulthood.
Cluster Headache Overview
Cluster headaches are the most common primary headache types known as trigeminal autonomic cephalgias (TACs). It is not clear exactly why cluster headaches occur. Research shows that during an attack, there is more activity in the hypothalamus, an area of the brain that controls body temperature, hunger, and thirst. This area of the brain releases chemicals that cause blood vessels to widen, resulting in a greater blood flow to the brain. However, researchers also think there could be a genetic link relating to the cause of the condition.
Like other trigeminal autonomic cephalgias (TACs), cluster headache is a short-lasting unilateral headache with at least one autonomic symptom ipsilateral to the headache, such as lacrimation, nasal congestion, conjunctival injection, or aural fullness. The associated nasal congestion can sometimes lead to a misdiagnosis of “sinus headache,” and patients are often managed by decongestants, which are ineffective for cluster headaches. These headaches can occur every other day to eight times a day. They usually occur at approximately the same time of day, most often at night. Most patients are episodic, with daily attacks for weeks to months and remission for months to years.
Some risk factors for Cluster Headaches include male gender, age of more than 30, consumption of alcohol, prior brain surgery or trauma, and family history. Symptoms of cluster Headaches are a red and watering eye drooping and swelling of 1 eyelid, a smaller pupil in 1 eye, a sweaty face, and a blocked or runny nostril.
Cluster headaches are either Episodic (typically lasting from 1 week to 3 months) or Chronic (persist for several months, 1 year, or longer) depending upon the period of remission and others.
Cluster Headache Epidemiology
The Cluster Headache epidemiology section provides insights into the historical and current Cluster Headache patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.
The epidemiology section of the Cluster Headache market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
Key Findings
- According to a study by (Schor et al., 2021) 2021, among the 1,604 subjects, the pediatric onset of cluster headache was found in 27.5% (341/1583) of participants, and only 15.2% (52/341) of participants with pediatric-onset were diagnosed before the age of 18. Men are more likely to have episodic cluster headaches between ages 10 and 50.
- As per the literature review by (Schor et al., 2021), in the US, in 2021, an overwhelming majority of respondents had at least one autonomic feature (99.0%, 1588/1604) and had restlessness (96.6%, 1550/1604), but many also had prototypical migrainous features including photophobia or phonophobia (50.1%, 804/1604), pain aggravated by physical activity (31.4%, 503/1604), or nausea and vomiting (27.5%, 441/1604).
- After searching for all population-based studies on the epidemiology of cluster headache published as a full paper in a scientific journal or book as referenced by MedLine, EMBASE, and currents contents up to August 2007, Fischera et al. (2008) in Germany, revealed that the pooled data showed a lifetime prevalence of 124 per 100,000 and a 1-year prevalence of 53 per 100,000. The overall sex ratio was 4.3 (male to female); it was higher in chronic cluster headache (15.0) compared with episodic cluster headache (3.8).
- As per the literature review by Imai et al. (2011), in 2011 out of 86 subjects, Chronic cluster headache was observed in 3.5% of patients. More than half of patients (68.9%) reported feelings of restlessness during headache episodes, and 42.9% reported restless behavior in Japan.
Cluster Headache Market Outlook
Cluster Headache currently lacks a cure. The current treatment aims to relieve some symptoms, shorten the periods of headaches, and reduce their frequency.
Medications commonly used include fast-acting treatment options like Inhaling 100% oxygen, which could reduce symptoms within 15 min; injectable sumatriptan (Imitrex) works by narrowing swollen blood vessels in the brain, which helps relieve the pain of cluster headaches; dihydroergotamine stops the release of natural substances in the brain that contribute to headache pain; intranasal lidocaine blocks the neural transmission of the sphenopalatine ganglion, thus relieving pain; corticosteroids suppress the inflammation; ergotamine (Ergomar) works by temporarily narrowing blood vessels throughout the body and anesthetic on the occipital nerve injecting anesthetic can numb this nerve, which is at the back of the head. As a result, pain messages that travel along the nerve pathway are blocked.
In 2019, Eli Lilly and Company announced that the US FDA has approved EMGALITY (galcanezumab-gnlm) injection (300 mg) for treating episodic cluster headaches in adults.
Promising emerging treatment options are under investigation for managing Cluster Headache. These include targeted therapies that modulate specific pathways involved in developing the disease. These emerging treatments offer hope for improving the management of Cluster Headaches by addressing key mechanisms involved in the disease etiology.
The COVID-19 pandemic positively impacted the growth of the cluster headache market, owing to a rise in the number of patients suffering from cluster headaches. In addition, many COVID-19 vaccines reported side effects of headache disorders such as cluster headaches, thus driving the growth of the market.
For instance, an article published in the National Library of Medicine (2022) stated that there were 628 cases of cluster headaches with the COMIRNATY vaccine in 2021. Alongside, the same source quoted that many patients in the Netherlands reported cluster headache episodes with frequent attacks after vaccination in 2021, driving the growth of the market.
Further, COVID-19 vaccinations triggered new cluster episodes in patients with cluster headaches, possibly by activating a pro-inflammatory state of the trigeminocervical complex.
According to DelveInsight, the Cluster Headache market in the 7MM is expected to change significantly during the forecast period owing to its changing epidemiology and the anticipated treatments.
Cluster Headache Drug Chapters
Cluster Headache Marketed Drugs
EMGALITY (galcanezumab-gnlm): Eli Lilly and Company
Galcanezumab-gnlm is a humanized IgG4 monoclonal antibody specific for calcitonin-gene related peptide (CGRP) ligand. By recombinant DNA technology, galcanezumab-gnlm is produced in Chinese Hamster Ovary (CHO) cells. Galcanezumab-gnlm comprises two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains and has an overall molecular weight of approximately 147 kDa.
Mechanism of action: Galcanezumab-gnlm is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
In June 2019, Eli Lilly and Company announced that the US FDA has approved EMGALITY (galcanezumab-gnlm) injection (300 mg) as the first and only medication for treating episodic cluster headaches that reduces the frequency of attacks in adults.
Emerging Cluster Headache Drugs
The currently available treatments for Cluster Headaches aim to mitigate the complications associated with the symptoms of the condition. The Cluster Headache market dynamics are expected to change, primarily due to increased healthcare expenditure worldwide. The rise in demand for novel therapies such as biologics, increased awareness about treatment options, and increased research and development to develop safe and efficacious drugs for cluster headache treatment offer lucrative opportunities to key players in the cluster headache market. Cluster Headaches Market players such as H. Lundbeck A/S, Clexio Biosciences, and others are actively developing Cluster Headache treatments.
Eptinezumab (anti-CGRP mAb): H. Lundbeck A/S
Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headaches. It is currently in Phase III of clinical development for Cluster Headache.
CLE-500: Clexio Biosciences
CLE-500 is an intranasal drug–device combination that targets a specific nerve pathway at the sphenopalatine ganglion, a ganglion associated with Cluster Headache attacks. By blocking this nerve pathway, it aims to relieve pain within 15 min.
Note: Detailed emerging therapies assessment will be provided in the final report...
Cluster Headache Market Segmentation
DelveInsight’s ‘Cluster Headache Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a detailed outlook of the current and future Cluster Headache market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Cluster Headache Market Size by Countries
The total Cluster Headache market size is analyzed for individual countries (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan). The United States accounted for a larger portion of the 7MM market for Cluster Headache in 2022 due to the high prevalence of the condition and the higher cost of treatments. This dominance is predicted to continue with the potential early entry of new products.
Cluster Headache Market Size by Therapies
Systemic scleroderma Market Size by Therapies is categorized into ergot derivatives, calcium channel blockers, Triptans, Somatostatin, local anesthetic nasal drops, corticosteroids, anti-seizure medications, anesthetic on the occipital nerve, and others, Eptinezumab (anti-CGRP mAb) a drug in the developmental pipeline of Lundbeck is likely to get approval. EMGALITY (galcanezumab-gnlm) by Elli Lilly is approved by the US FDA for episodic cluster headaches in adults.
Note: Detailed market segment assessment will be provided in the final report...
Cluster Headache Drugs Uptake
This section focuses on the sales uptake of potential Cluster Headache drugs that have recently launched or are anticipated to be launched in the Cluster Headache market between 2019 and 2032. It estimates the market penetration of Cluster Headache drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the drug’s probability of success (PoS) in the Cluster Headache market.
The emerging Cluster Headache therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Cluster Headache market.
Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Cluster Headache.
Cluster Headache Market Access and Reimbursement
DelveInsight’s ‘Cluster Headache Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a descriptive overview of the market access and reimbursement scenario of Cluster Headache.
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with the current Cluster Headache market trends and fill gaps in secondary findings, we interview KOLs and SMEs working in the Cluster Headache domain. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Cluster Headache market trends. This will support the clients in understanding potential upcoming novel treatments by identifying the overall scenario of the market and the Cluster Headache unmet needs.
Cluster Headache: KOL Insights
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the Departments of Neurology and Anesthesiology, University of Münster, Münster, Germany.
“Despite unique clinical features, such as patients experiencing attacks in a circannual pattern and often with a circadian rhythm within bouts, cluster headache patients often are misdiagnosed, mismanaged and have a delay in diagnosis.”
“As our understanding of the pathophysiology of cluster headaches has evolved, new therapeutic options, such as calcitonin gene-related peptide monoclonal antibodies, non-invasive vagal nerve stimulation, and sphenopalatine ganglion stimulation, have proved to have efficacy in the treatment of cluster headache.”
Note: Detailed assessment of KOL Views will be provided in the full report on Cluster Headache...
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Cluster Headache Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Cluster Headache Pipeline Development Activities
The Cluster Headache report provides insights into Cluster Headache Clinical Trials within Phase II and III stages. It also analyses Cluster Headache Companies involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers collaborations, acquisition and merger, licensing, patent details, and other information for emerging Cluster Headache therapies.
Cluster Headache Report Insights
- Cluster Headache Patient Population
- Cluster Headache Therapeutic Approaches
- Cluster Headache Pipeline Analysis
- Cluster Headache Market Size and Trends
- Cluster Headache Market Opportunities
- Impact of Upcoming Cluster Headache Therapies
Cluster Headache Report Key Strengths
- 10 years Forecast
- The 7MM Coverage
- Cluster Headache Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Cluster Headache Market
- Cluster Headache Drugs Uptake
Cluster Headache Report Assessment
- Cluster Headache Current Treatment Practices
- Cluster Headache Unmet Needs
- Cluster Headache Pipeline Product Profiles
- Cluster Headache Market Attractiveness
- Cluster Headache Market Drivers
- Cluster Headache Market Barriers
Key Questions Answered In The Cluster Headache Market Report
- What are the key findings of the market across 7MM, and what country will have the largest Cluster Headache market size during the forecast period (2023–2032)?
- At what CAGR is the Cluster Headache market, and is epidemiology expected to grow in the 7MM during the forecast period (2023–2032)?
- How would the unmet needs impact the Cluster Headache market dynamics and subsequently influence the analysis of related trends?
- What would be the forecasted patient pool of Cluster Headache in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- What are the latest advancements in novel therapies, targets, mechanisms of action, and technologies being developed to address the limitations of existing therapies for Cluster Headaches?
- How many companies are currently engaged in the development of therapies for the treatment of Cluster Headaches?
Frequently Asked Questions
What are the upcoming Market trends of Cluster headaches?
The rise in investments in developing effective medications for cluster headaches is the upcoming trend in the market.
What is the leading drug class of the cluster headache market?
Triptans is the leading drug class in the cluster headache market.
Which companies are the leading players in the cluster headache market?
Major Key players that operate in the global cluster headache market are Eli Lilly and Company, Clexio Biosciences, and H. Lundbeck A/S.
Is the market expecting any changes during the forecast period (2023-2032)?
Yes, the increasing prevalence of Cluster Headache and the launch of emerging drugs is expected to change the market with a considerable CAGR.
How do these headaches compare with migraine?
Unlike migraine, which is more common in females, cluster headache is more common in males, about three males to every female. It is much less common than migraine. In migraine, we consider about 15% of the population, and in the cluster, it is about 0.1% of the population. It is about as common as multiple sclerosis. Migraine is so common that it swamps everything else that happens in the headache world.
